Business Wire

Swave Photonics, QART Medical, and PhosPrint win big at 2023 SPIE Startup Challenge

1.2.2023 21:58:00 EET | Business Wire | Press release

Share

Yesterday, at a ceremony during SPIE Photonics West, Swave Photonics – with their Holographic eXtended Reality chips based on proprietary diffractive photonics technology – was announced the winner of the $10,000 top prize at the 13th annual SPIE Startup Challenge.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005834/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jenoptik’s Ralf Kuschnereit, far left, Swave Co-Founder and Chief Product Officer Theo Marescaux, Swave CEO Mike Noonen, and 2023 SPIE Vice President Peter de Groot. Credit: Joey Cobbs.

QART Medical, utilizing biophotonics and data for 3D analysis of sperm cells during IVF, received $5,000 for second place. PhosPrint came in third, winning $2,500, with their novel bioprinting technology that repairs in vivo human tissue during surgery. All cash prizes are provided by SPIE Startup Challenge Founding Partner Jenoptik.

The SPIE Startup Challenge, a pitch competition held annually by SPIE, the international society for optics and photonics, showcases new businesses, products, and technologies that address critical needs by utilizing photonics in the areas of healthcare and deep tech. This year’s finalists included innovations in medical diagnostics, medical imaging, food safety, and display technology.

“It’s a privilege just to present to a such distinguished audience,” says Swave Photonics CEO Mike Noonen. “Participating at the Startup Challenge was an award in itself, but to actually win first-place recognition, well, our team is very excited. We really want to thank the sponsors and SPIE and Photonics West for the opportunity.”

“It's very nice to get the acknowledgement,” notes QART Medical CEO and Co-Founder Alon Shalev. “The judges were very supportive, and they gave us good insights yesterday in the preparation session. I think SPIE Photonics West is a wonderful, wonderful event, and a great opportunity to see and meet people. Being acknowledged is always nice, and this feels like a real achievement.”

“It was a great experience for me,” adds Chief Technology Officer and Co-Founder of PhosPrint Ioanna Zergioti. “It was exciting for us to have the opportunity to present our startup at the SPIE Startup Challenge. It was especially great to work with the judges, and to get feedback from senior investors in the field.”

The 2023 SPIE Startup Challenge was supported by Founding Partner Jenoptik; Lead Sponsors Edmund Optics, Hamamatsu, MKS Instruments, and Thorlabs; and Supporting Sponsors NextCorps Luminate and Photonics Media. The competition judges who vetted the applicants for their business models, financial cases, and competitive advantages included Jenoptik’s Kristin Holzhey, MKS Instruments’ Marc D. Himel, Edmund Optics' Agnes Hübscher, NextCorps Luminate’s Sujatha Ramanujan, Hamamatsu Ventures’ Richard Oberreiter, and Thorlabs’ Garrett Cole.

Light-based technologies enable developments in a proliferating number of areas, from healthcare and high-speed communications to quantum computing, AR/VR/MR, and self-driving vehicles. The SPIE Startup Challenge is an annual entrepreneurial pitch competition for new businesses that utilize optics and photonics to create innovative products, applications, and technologies. Startup Challenge winners that have gone on to wider commercial success include Cellino Biotech, Double Helix Optics, PhotoniCare, C. Light Technologies, Circle Optics, and In A Blink.

About SPIE

SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper19.2.2026 23:08:00 EET | Press release

Newmont Corporation (NYSE: NEM, ASX: NGT, PNGX: NEM) (Newmont or the Company) reported gold Mineral Reserves ("reserves") of 118.2 million attributable ounces at the end of 2025 compared to 134.1 million attributable ounces at the end of 2024, mainly driven by the divestment of assets in 2025. Newmont's portfolio includes significant reserves from other metals, including 12.5 million attributable tonnes of copper reserves and 442 million attributable ounces of silver reserves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219894602/en/ Percentage of Gold Reserves by Jurisdiction "In 2025, Newmont maintained its position of having the industry's largest gold reserve base, declaring 118 million ounces of reserves, representing decades of production life with meaningful upside," said Natascha Viljoen, Newmont's President and Chief Executive Officer. "Through the disciplined application of technical rigor in our leading expl

Unveiling NVIDIA Solution Center: Grid Dynamics’ Family of AI Solutions to Cut Costs for Retail and Manufacturing19.2.2026 23:05:00 EET | Press release

Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a premier AI transformation partner for the Fortune 1000, today announced the launch of its NVIDIA Solution Center. This suite of ready-to-deploy AI applications helps retail and manufacturing enterprises move away from costly, recurring SaaS licenses and subscription fees toward high-performance, NVIDIA-powered solutions. Learn more by reading NVIDIA’s recent announcement. The NVIDIA Solution Center is derived from Grid Dynamics’ proven successful deployments at customers across the retail and manufacturing industries. The suite leverages NVIDIA’s software components including Metropolis, Omniverse, and Nemotron. All solutions offer flexible deployment at the edge, in on-premises datacenters, or in the cloud, enabling customers to achieve an optimal balance between inference cost, latency, privacy, and other operational requirements. The suite covers the following use cases, tailored to the needs of retail and manufacturing

Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results19.2.2026 23:01:00 EET | Press release

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219293814/en/ Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results “Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind down. We grew our core Rimini Support™ subscription billings and launched our next generation Agentic AI ERP solutions that can be easily and quickly deployed over the top of existing ERP Software without the cost or risk of unnecessary ERP Software upgrades, migrations or replatforming,” said

Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 19:25:00 EET | Press release

Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of

Positive Phase 3 Data Demonstrate Potential for ENTYVIO ® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 19:00:00 EET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), show vedolizumab’s promising efficacy and safety profile in a patient population where therapy options remain limited.With KEPLER, Takeda is continuing to generate deeper scientific insights and identify additional patient populations who may benefit from vedolizumab, a cornerstone therapy for adults with ulcerative colitis. Vedolizumab is marketed under the trade name ENTYVIO®*. “Ulcerative colitis is a life-altering diagnosis for young patients and their families, often leaving t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye